- TG Therapeutics press release (NASDAQ:TGTX): Q4 GAAP EPS of $0.15 beats by $0.06.
- Revenue of $108.19M (+146.1% Y/Y) beats by $7.52M.
- Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024. We anticipate that our cash, cash
TG Therapeutics GAAP EPS of $0.15 beats by $0.06, revenue of $108.19M beats by $7.52M
